Nkarta to present nkx019 phase 1 dose escalation data at european hematology association 2023 congress and 17th international conference on malignant lymphoma

South san francisco, calif., may 11, 2023 (globe newswire) -- nkarta, inc. (nasdaq: nktx), a biopharmaceutical company developing engineered natural killer (nk) cell therapies, today announced that it will present preliminary data from its phase 1 dose escalation clinical trial of nkx019 at two upcoming scientific conferences in june 2023: the european hematology association (eha) 2023 hybrid congress and the 17th international conference on malignant lymphoma (17-icml). nkx019 is an allogeneic, off-the-shelf cell therapy candidate comprising nk cells derived from healthy donors and engineered to target the b-cell antigen cd19.
NKTX Ratings Summary
NKTX Quant Ranking